Nicotinamide pharmacokinetics in humans: effect of gastric acid inhibition, comparison of rectal vs oral administration and the use of saliva for drug monitoring
1996

Nicotinamide Pharmacokinetics in Humans

Sample size: 10 publication Evidence: moderate

Author Information

Author(s): MRL Stratford, MF Dennis, P Hoskin, H Phillips, RJ Hodgkiss, A Rojas

Primary Institution: Gray Laboratory Cancer Research Trust and CRC Clinical Tumour Biology and Radiation Therapy Group, Mount Vernon Hospital

Hypothesis

Does inhibiting gastric acid secretion improve the pharmacokinetics of nicotinamide?

Conclusion

Inhibiting gastric acid production and using rectal administration did not improve the pharmacokinetics of nicotinamide.

Supporting Evidence

  • Suppression of gastric acid production had no significant effect on the rate of uptake of nicotinamide.
  • Absorption via the rectal route was slow and variable, yielding lower plasma levels than oral dosing.
  • Saliva monitoring showed that the time to peak levels of nicotinamide correlated well with plasma levels.

Takeaway

This study looked at how nicotinamide is absorbed in the body and found that changing how it's taken doesn't help it work better.

Methodology

The study involved administering nicotinamide orally and rectally to volunteers and measuring plasma and saliva concentrations.

Potential Biases

Potential bias due to the small number of participants and variability in individual responses.

Limitations

The study had a small sample size and variability in absorption rates.

Participant Demographics

Five volunteers and one patient, with a mix of genders and varying weights.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication